Post-streptococcal glomerulonephritis primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 20: Line 20:


==Primary Prevention==
==Primary Prevention==
*There are no established measures for the primary prevention of [disease name].
*Effective measures for the primary prevention of post-streptococcal glomerulonephritis include:
*There are no available vaccines against [disease name].
**Improve hygiene
OR
**Better housing
*Effective measures for the primary prevention of [disease name] include:
**Prevent overcrowding
**[Measure1]
*A 26-valent vaccine is recommended for children to prevent post-streptococcal glomerulonephritis.
**[Measure2]
 
**[Measure3]
OR
*[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
**[Strategy 1]
**[Strategy 2]
**[Strategy 3]
==References==
==References==



Revision as of 14:28, 17 May 2018

Post-streptococcal glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Post-streptococcal glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Post-streptococcal glomerulonephritis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Post-streptococcal glomerulonephritis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Post-streptococcal glomerulonephritis primary prevention

CDC on Post-streptococcal glomerulonephritis primary prevention

Post-streptococcal glomerulonephritis primary prevention in the news

Blogs on Post-streptococcal glomerulonephritis primary prevention

Directions to Hospitals Treating Post-streptococcal glomerulonephritis

Risk calculators and risk factors for Post-streptococcal glomerulonephritis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Primary Prevention

  • Effective measures for the primary prevention of post-streptococcal glomerulonephritis include:
    • Improve hygiene
    • Better housing
    • Prevent overcrowding
  • A 26-valent vaccine is recommended for children to prevent post-streptococcal glomerulonephritis.

References

Template:WH Template:WS